Brief: Genprex Publishes Positive Clinical Data From Phase 1 Portion Of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy In Non-Small Cell Lung Cancer At 2023 ASCO Annual Meeting

Genprex

25/05/2023 23:11

May 25 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX PUBLISHES POSITIVE CLINICAL DATA FROM PHASE 1
PORTION OF
ACCLAIM-1 CLINICAL TRIAL EVALUATING REQORSA® IMMUNOGENE THERAPY
IN NON-SMALL CELL LUNG CANCER AT THE 2023 ASCO ANNUAL MEETING

Source text for Eikon:  ID:nPn8gcQbya 
Further company coverage:  GNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))